Clinical trial
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving…
NCT00489905 · Hospital Authority, Hong Kong, Other · Completed
Key facts
| NCT number | NCT00489905 |
|---|---|
| Title | Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer |
| Official title | Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer |
| Lead sponsor | Hospital Authority, Hong Kong, Other |
| Collaborators | Baxter Healthcare Corporation Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms, Bone Density |
| Intervention type | Drug |
| Interventions | Zolderonic acid (Zometa) |
| Enrollment | 24 |
| Start date | Apr 1, 2005 |
| Completion | May 1, 2008 |
| First posted | Jun 21, 2007 |
| Last update posted | Oct 23, 2013 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: